The drug is an siRNA that targets the nucleocapsid "N" gene of the RSV genome, which is required for viral replication.

Earlier this year, Alnylam began phase II testing of an inhalable form of the drug in adult lung transplant patients naturally infected with RSV. The company intends to begin a trial in pediatric patients later this year.

In June, Kyowa Hakko Kogyo acquired the rights to ALN-RSV01 in Asia.

AGN-745 is an siRNA targeting vascular endothelial growth factor receptor-1.

Allergan acquired the drug from its developer, Sirna Therapeutics, in 2005.

AGN-745 is currently under phase II testing.

The therapy involves using granulocyte colony stimulating factor to mobilize stem cells in AIDS-related lymphoma patients. Once the stem cells begin circulating peripherally, they can be collected, isolated, and genetically modified with a lentiviral vector containing three therapeutic genes: DNA that encodes for shRNAs targeting the tat-rev exon, a ribozyme that cleaves the mRNA for CCR5, and a nucleolar-localizing TAR decoy.

The shRNA technology was developed by Benitec, although the drug's development is being overseen by City of Hope.

An ongoing trial of the treatment in adults infected with HIV-1 and AIDS-related lymphoma began last year.

The drug is an siRNA targeting the M2 subunit of ribonucleotide reductase.

This year, Calando began a phase I trial of the drug in patients with solid tumors that are refractory to standard-of-care therapies, marking the first time a formulated RNAi drug has been administered to humans.

Bevasiranib is an siRNA that targets VEGF.

Developed by Acuity Pharmaceuticals, which was acquired by Opko in 2007, the drug was the first RNAi drug to enter human trials.

Bevasiranib is currently in phase III testing for AMD. The drug had previously been evaluated in a phase II trial for diabetic macular edema.

The drug is an siRNA targeting RTP-801, a gene found to play a role in angiogenesis, vascular permeability, and retinal neuron death.

Pfizer acquired the molecule from Quark Pharmaceuticals, as well as the use of RTP-801 as a target for ocular disease, in 2006.

PF-4523655 is currently in phase II trials.

The drug is an siRNA is designed to temporarily inhibit the transcription factor human p53, which is associated with DNA repair and apoptosis.

According to Quark, this strategy in acute settings such as acute kidney injury is expected to delay apoptosis and thereby allow "natural repair mechanisms to restore normal DNA and cellular integrity."

The drug last year entered an ongoing phase I trial in patients undergoing cardiovascular surgery, making it the first systemic RNAi drug tested in humans.

The drug is a long, dsRNA targeting tenascin-C.

Developed at the Polish Academy of Sciences, the drug has already been tested in patients with glioblastoma multiforme in Poland.

PC is a rare autosomal skin disorder characterized by hypertrophic nail dystrophy and focal palmoplantar keraderma with blisters.

TD101 is an siRNA that targets mutant forms of keratin 6a and keratin 16 responsible for the condition.

Earlier this year, TransDerm began a one-patient phase Ib study of an intradermally injected form of the drug.